RE:RE:RE:RE:RE:Ground Hog Day... Is it any wonder that information presented in this way and released into an information void as to overall Corporate progress (evidently now lacking even the meagre comfort of the minimally informative and ambiguous so-called Quarterly) should be received so negatively?
The Company’s real value lies in it’s` control over Sherri`s metal-based photo-sensitisers until 2054. Rutherrin is the first of such compounds likely to demonstrate their true potential and should be showcased since it is an enhancement exclusive to the Company but instead we are left to wonder when or even if it will ever even be used in humans.
Big Pharma must be loving it - and we blame the shorters??